|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
CD70 expression was associated with the presence of a precursor papillary thyroid carcinoma and the presence of BRAF V600E mutations in the anaplastic thyroid cancer lesion.
|
28383817 |
2017 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF(V</span>600E) was more frequent in PTC with concomitant lymphocytic infiltration.
|
23469895 |
2013 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid cancer cells (BHP 17-10) but is missing in rearranged in transformation/papillary thyroid carcinoma-1 rearrangement thyroid cancer cells (BHP 2-7).
|
18202121 |
2008 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Incorporating the use of the recently identified BRAF V600E point mutation, a highly specific biomarker for papillary carcinoma of the thyroid, may provide a useful adjunct in assessing the biologic nature of morphologically bland-appearing thyroid inclusions in cervical lymph nodes.
|
17159251 |
2006 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The B-Raf proto-oncogene serine∕threonine kinase (BRAF) V600E (BRAF(V600E)) mutation represents a very specific marker for papillary thyroid carcinoma (PTC), including microcarcinomas (PTMCs).
|
30534813 |
2018 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
V600E BRAF gene mutation was demonstrated in 19/43 malignant nodules, in 0/56 benign nodules and in only 1/54 indeterminate nodules that, after histology, turned out to be at a papillary thyroid carcinoma.
|
25194426 |
2014 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation is the most prevalent genetic aberration in papillary thyroid carcinomas (PTCs), and it is found exclusively in RET/PTC-negative tumors.
|
18235983 |
2008 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Coexisting BRAF V600E and TERT promoter mutations have a robust synergistic impact on the aggressiveness of PTC, including a sharply increased tumor recurrence and patient mortality, while either mutation alone has a modest impact.
|
26733501 |
2016 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We correlated the BRAF V600E mutation with both clinical-pathological features and the degree of neoplastic infiltration to redefine the reliability of the actual system of risk stratification in a large selected group of PTCs smaller than 20 mm.
|
20631031 |
2010 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors the oncogenic T1799A BRAF mutation.
|
19883729 |
2010 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF(V600E) in PTC predicts an increased risk of lymph node metastasis, extra-thyroidal extension and reduced disease-free survival.
|
27138882 |
2016 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We further discuss a case with a single BRAF V600E cytological mutant lacking a postoperative PTC diagnosis and discuss the limitations of BRAF V600E detection using puncture elution fluid.
|
31529211 |
2019 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
It is not clear that the BRAF(V600E) mutation is useful for prediction of poor prognosis of PTC.
|
21803329 |
2012 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Assessment of correlations between BRAF V60</span>0E mutations and papillary thyroid cancer progression needs to be performed.
|
23725167 |
2013 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The SUVmax of PTCs was significantly higher if they carried the BRAF V600E mutation (11.3 ± 2.0, compared with 5.7 ± 1.4 for wild type BRAF tumors, Mann-Whitney test, p = 0.016).
|
26513490 |
2016 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation is a useful diagnostic marker for differentiating papillary thyroid carcinoma from benign thyroid nodules, especially in BRAF(V600E) -prevalent populations such as in Korea.
|
21707687 |
2011 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The TERT promoter and the BRAF V600E mutations were identified from PTC samples.
|
26727717 |
2016 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The predominant BRAF V600E mutation has not been detected in benign thyroid tissue so far, so consequently, this assumedly pathognomonic alteration is qualified to improve the preoperative diagnosis of PTC.
|
20652698 |
2010 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A total of 47 intracerebral melanoma metastases and 21 primary papillary thyroid carcinomas were evaluated by direct sequencing of BRAF and by immunohistochemistry using the BRAF V600E mutation-specific antibody clone VE1.
|
21638088 |
2011 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These results suggest that ZNF703 may be of potential use as a new marker for PTC prognosis and therapy that functions independent of BRAF V600E expression.
|
30361900 |
2018 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
|
26950846 |
2016 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation, which accounts for about 60-80% papillary thyroid carcinoma(PTC), has been identifiedas a prognostic marker for risk stratification of PTC patients.
|
24228637 |
2013 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Seven of the 9 indeterminate and suspicious cases with the BRAF V600E mutation had surgical follow-up, and they were all confirmed to be PTC.
|
30620446 |
2019 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF(V600E), the most frequent mutation in adult patients, is present in approximately 50% of PTC.
|
21049459 |
2011 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
PTC with BRAF V600E mutation showed higher expression of ATX, LPA1, LPA2, and LPA3 than PTC without BRAF V600E mutation (p < 0.001).
|
31455351 |
2019 |